menu
    • menu
    [{"orgOrder":0,"company":"Metaba","sponsor":"MAX BioPharma","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Collaboration","leadProduct":"Inapplicable","moa":"||TGF-beta","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Preclinical","graph3":"Metaba","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Metaba \/ MAX BioPharma","highestDevelopmentStatusID":"4","companyTruncated":"Metaba \/ MAX BioPharma"},{"orgOrder":0,"company":"Metaba","sponsor":"MAX BioPharma","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"Inapplicable","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery Platform","graph3":"Metaba","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Metaba \/ Metaba","highestDevelopmentStatusID":"3","companyTruncated":"Metaba \/ Metaba"}]

    Find Clinical Drug Pipeline Developments & Deals by Metaba

    Menu

    Metaba

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Metaba

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            Metaba

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed,Inapplicable

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Discovery Platform

                            Recipient : MAX BioPharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Metaba, MAX BioPharma Achieve Key Milestone on Next-Gen Oxysterol-Based Antibiotics

                            Details : Company is focused on developing oxysterol-based drug candidates targeting bacterial infections like tuberculosis, urinary tract infections, Lyme disease and MRSA.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            February 20, 2025

                            Lead Product(s) : Undisclosed,Inapplicable

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Discovery Platform

                            Recipient : MAX BioPharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Metaba

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            Metaba

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Oxysterol,Inapplicable

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Study Phase : Preclinical

                            Sponsor : MAX BioPharma

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            MAX BioPharma and Metaba Announce Collaboration on Metabolomics Studies

                            Details : The collaboration focuses on developing Oxy210 (oxysterol), a small-molecule antifibrotic, evaluated in preclinical studies for non-alcoholic steatohepatitis and pulmonary fibrosis.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            February 26, 2024

                            Lead Product(s) : Oxysterol,Inapplicable

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Highest Development Status : Preclinical

                            Sponsor : MAX BioPharma

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth